CompletedPhase 1NCT01502917
Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
Studying OBSOLETE: Brain stem tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Y-mAbs Therapeutics
- Principal Investigator
- Mark Souweidane, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Radioactive iodine-labeled monoclonal antibody omburtamab(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 2-21 years · All sexes
- Timeline
- 2011 – 2022
Study locations (2)
- Weill Medical College of Cornell University, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Collaborators
Memorial Sloan Kettering Cancer Center
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01502917 on ClinicalTrials.gov